Climb Bio Inc stock is traded at $11.73, with a volume of 1,444,785. It is up +6.54% in the last 24 hours and up +6.64% over the past month. Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
Previous Close:
$11.01
Open:
$10.96
24h Volume:
1,444,785
Relative Volume:
1.06
Market Cap:
$689.00M
Revenue:
-
Net Income/Loss:
-$52.79M
P/E Ratio:
-
EPS:
-$0.7789
Net Cash Flow:
-$53.49M
1W Performance:
+20.31%
1M Performance:
+6.64%
6M Performance:
+3.17%
1Y Performance:
+551.67%
1-Day Range:
$10.62$11.87
1-Week Range:
$8.49$11.87
52-Week Range:
$1.64$18.33
Climb Bio Inc Stock (CLYM) Company Profile
Name
Climb Bio IncSector
HealthcareIndustry
BiotechnologyPhone
1-866-857-2596Address
20 WILLIAM STREET, WELLESLEY HILLS, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS